By creating an account you agree to our Terms of Service and Privacy Policy.
Already have an account? Sign in
$215.59
No Data
N/A
Total outstanding shares value
Latest reported
Net Income / Revenue
Prior year same period
Leverage risk indicator
0.00%
Annualized Return
No data
Aug 25, 2026
The latest breakthrough in personalized cancer treatments isn’t just a win for oncology—it is the opening bell for a massive capital reallocation. Staring down a catastrophic wave of late-2020s patent
